DFIN to Announce First-Quarter Results and Host Investor Conference Call on April 30, 2025

PR Newswire


CHICAGO
, April 16, 2025 /PRNewswire/ — Donnelley Financial Solutions (NYSE: DFIN) will hold a conference call and webcast on Wednesday, April 30, 2025 at 9:00 a.m. Eastern time to discuss its first-quarter fiscal year 2025 financial results, provide a general business update and respond to analyst questions.

A live webcast of the call will also be available on the Company’s investor relations website. Please visit investor.dfinsolutions.com at least fifteen minutes prior to the start of the event to register, download and install any necessary audio software.

If you are unable to participate live, a replay of the webcast will be available following the conference call on the Company’s investor relations website, along with the earnings press release, and related financial tables.

DFIN’s financial report for the first quarter will be released before the market opens on Wednesday, April 30, 2025 via a filing with the SEC on Form 8-K and will also be posted on the Company’s investor relations website.

About Donnelley Financial Solutions (DFIN)
DFIN is a leading global provider of innovative software and technology-enabled financial regulatory and compliance solutions. We provide domain expertise, enterprise software and data analytics for every stage of our clients’ business and investment lifecycles. Markets fluctuate, regulations evolve, technology advances, and through it all, DFIN delivers confidence with the right solutions in moments that matter. Learn about DFIN’s end-to-end risk and compliance solutions online at DFINsolutions.com or you can also follow us on X (formerly Twitter) @DFINSolutions or on LinkedIn.

Investor Contact:

Mike Zhao

Investor Relations
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dfin-to-announce-first-quarter-results-and-host-investor-conference-call-on-april-30-2025-302430668.html

SOURCE Donnelley Financial LLC

Baijiayun and Xinlantian Reached Strategic Cooperation to Use AI Technology to Assist the Rehabilitation of Tens of Millions of Autistic Children

PR Newswire


BEIJING
, April 16, 2025 /PRNewswire/ — Baijiayun Group Ltd (“Baijiayun” or the “Company”) (NASDAQ: RTC), a one-stop AI video solution provider, today announced that we have reached a strategic cooperation with Beijing Xinlantian Education Technology Co., Ltd. (hereinafter referred to as “Xinlantian”). This cooperation marks that Baijiayun, with its cutting – edge exploration in AI and large – language model technologies, will combine with Xinlantian’s professional accumulation in the field of rehabilitation training for autistic children. Together, they will provide more efficient and personalized rehabilitation training programs for autistic children.

As the AI video technology service provider with the most in-depth comprehension of education, Baijiayun brings robust technical expertise in AI large model technologies. Xinlantian, through ten years of entrepreneurial experience, has accumulated specialized rehabilitation philosophies and a wealth of practical cases. The two parties will jointly develop an intelligent diagnostic assistance platform to create personalized rehabilitation plans tailored to each child’s unique condition and training needs. Leveraging big data analytics and machine learning algorithms, the platform will enable real-time monitoring of training progress and outcomes. This precision-oriented approach ensures every child receives optimally customized rehabilitation programs, maximizing progress within shorter timeframes.

Additionally, Baijiayun will provide comprehensive support including SCRM management, online school platforms, intelligent diagnostics, and regulatory tools. These resources will empower Xinlantian to achieve refined management of parent leads, unified administration of teaching operations, real-time diagnosis of developmental challenges, and intelligent oversight of nationwide branches. Through these enhancements, Xinlantian will elevate service quality to deliver more holistic and professional rehabilitation services for autistic children and their families.

This strategic collaboration represents not only a convergence of technologies and resources but also an innovative exploration of partnership models. Through joint efforts, the two companies aspire to pioneer advanced and effective rehabilitation solutions for this special needs community. Mr. Yi Ma, CEO of Baijiayun, stated: “We are committed to driving educational innovation through AI technologies. The essence of AI lies in enabling businesses to deliver personalized services at scale. Our partnership with Xinlantian signifies a crucial step in applying AI to special needs education. We believe our combined efforts will bring precise, efficient rehabilitation to autistic children, igniting a beacon of hope for their future. This embodies how AI technology creates tangible social value.”

Company Contact:

Ms. Fangfei Liu 
Chief Financial Officer, Baijiayun Group Ltd
Phone: +86 25 8222 1596
Email: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/baijiayun-and-xinlantian-reached-strategic-cooperation-to-use-ai-technology-to-assist-the-rehabilitation-of-tens-of-millions-of-autistic-children-302430729.html

SOURCE Baijiayun Group Ltd

ENERGIZER HOLDINGS, INC. TO WEBCAST A DISCUSSION OF SECOND QUARTER FISCAL YEAR 2025 RESULTS ON MAY 6

PR Newswire


ST. LOUIS
, April 16, 2025 /PRNewswire/ — Energizer Holdings, Inc. (NYSE: ENR) will report its Second Quarter Fiscal Year 2025 results before the market opens on May 6. Energizer also will discuss its results during an investor conference call that will be webcast beginning at 10 a.m. ET. The call will be hosted by Mark LaVigne, Chief Executive Officer, and John Drabik, Chief Financial Officer.

All interested parties may access a live webcast of this conference call at www.energizerholdings.com, under the Investors and Events & Presentations tabs or by using the following link: 

https://app.webinar.net/6l5VGlBKO0z

For those unable to participate during the live webcast, a replay will be available on www.energizerholdings.com, under the “Investors,” “Events & Presentations” and “Past Events” tabs. 

About Energizer:

Energizer Holdings (“Energizer,” NYSE: ENR), headquartered in St. Louis, is one of the world’s largest manufacturers and distributors of primary batteries, portable lights, and auto care appearance, performance, refrigerant, and fragrance products. Our portfolio of globally recognized brands include Energizer, Armor All, Eveready, Rayovac, STP, Varta, A/C Pro, Refresh Your Car!, California Scents, Driven, Bahama & Co., LEXOL, Eagle One, Nu Finish, Scratch Doctor, and Tuff Stuff. As a global branded consumer products company, Energizer’s mission is to be the leader in our categories by better serving consumers and customers. Visit www.energizerholdings.com for more details.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/energizer-holdings-inc-to-webcast-a-discussion-of-second-quarter-fiscal-year-2025-results-on-may-6-302430448.html

SOURCE Energizer Holdings, Inc.

Vital Farms Publishes 2025 Impact Report, Underscoring Commitments to Long-Term, Positive Impact for all its Stakeholders

AUSTIN, Texas, April 16, 2025 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today published its 2025 Impact Report, which highlights the ongoing progress the company has made driving positive outcomes across its stakeholder community to fuel each stakeholder’s – and the company’s – continued success.

Vital Farms’ Impact strategy is centered around three key areas of focus within its organization, among its stakeholders, and in the communities where it operates: Building a resilient food system, fostering a people-first culture, and driving engaged and accountable oversight.

“Every decision we make as a company begins with our purpose, which is to improve the lives of people, animals and the planet through food, and that extends to our focus on creating long-term, positive impact for each of our stakeholders,” said Joanne Bal, General Counsel, Head of Impact, and Corporate Secretary of Vital Farms. “As a Certified B Corp, a Public Benefit Corporation, and our aspiration to become America’s most trusted food company, we are committed to continuing to raise the standards in the food industry and continuing to build a more engaging workplace for our crew.”

The 2025 Impact Report shares tangible progress Vital Farms has made against its Impact Goals, as well as other company accomplishments over the past year. This year’s highlights include:

Building a Resilient Food System:

  • Reduced operational emissions intensity by 17.7% at Egg Central Station (ECS), Vital Farms’ state-of-the-art egg-washing and packing facility in Springfield, Missouri since 2023.
  • Engaged nearly 50% of its farmer network in additional regenerative agriculture practices beyond existing principles like pasture rotation that all Vital Farms farmers already implement, with a goal to engage 100% of farmers on regenerative agriculture practices by the end of 2026.
  • Achieved LEED® Gold Certification at ECS, a symbol of excellence in environmental stewardship.

Fostering a People-First Culture:

  • Achieved Great Place to Work (GPTW) Certification by surpassing the 80% threshold required for certification in GPTW’s accreditation survey. The Great Place to Work Certification is a globally recognized credential that signifies excellence in workplace culture.
  • Achieved Elite Excellent 99% rating from an annual Safe Quality Food (SQF) audit, demonstrating rigorous standards, dedication to continuous improvements, and the food safety and quality culture embodied by Vital Farms crew.
  • Provided more than $600,000 in philanthropy toward strengthening the communities where Vital Farms operates – from its hometown of Austin to the Springfield area, where more than half of their crew members live and work, to their farmers’ communities.

Driving Engaged & Accountable Oversight:

  • Launched first company-wide Ethics Week, which included a panel discussion with Vital Farms board members, the launch of a revamped Code of Business Conduct and Ethics, and virtual ethics and compliance training for crew.
  • Set a goal for 95% of crew members to complete ethics and compliance training by the end of 2025 to continue driving accountability for fostering company-wide ethical culture.
  • Successfully recertified as a B Corp for the fourth time, administered by B Lab, an independent nonprofit that recognizes companies for meeting high standards of social environmental performance, accountability, and transparency.

The full 2025 Impact Report, including accomplishments, progress on Impact Goals, and standards-based metrics and disclosures can be found at www.vitalfarms.com/impact.

ABOUT VITAL FARMS

Vital Farms (Nasdaq: VITL) is a Certified B Corporation that offers a range of ethically produced foods nationwide. Started on a single farm in Austin, Texas in 2007, Vital Farms is now a national consumer brand that works with over 425 family farms and is the leading U.S. brand of pasture-raised eggs by retail dollar sales. Vital Farms’ ethics are exemplified by its focus on the humane treatment of farm animals and sustainable farming practices. In addition, as a Delaware public benefit corporation, Vital Farms prioritizes the long-term benefits of each of its stakeholders, including farmers and suppliers, customers and consumers, communities and the environment, and crew members and stockholders. Vital Farms’ products, including shell eggs, butter, hard-boiled eggs, and liquid whole eggs, are sold in approximately 24,000 stores nationwide. Vital Farms pasture-raised eggs can also be found on menus at hundreds of foodservice operators across the country. For more information, visit https://vitalfarms.com/.

Media:

Rob Discher
[email protected]

Investors:

John Mills
[email protected]



Beneficient Adjourns Annual Meeting of Stockholders

DALLAS, April 16, 2025 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, announced today that the Company’s Annual Meeting of Stockholders, which had been previously adjourned to 9:00 a.m. Central time today, April 16, 2025, has been once again adjourned to allow for more time for stockholders to vote.

At this time, there were not present, by remote communication or by proxy, a sufficient number of shares of the Company’s common stock to constitute a quorum. The Company’s Board of Directors continues to believe that that all of the proposals contained in the proxy statement are advisable and in the best interests of the Company’s stockholders to consider and act upon. Therefore, the Company adjourned the Annual Meeting.

The meeting has been scheduled to reconvene on April 30, 2025, at 9:00 a.m. Central time and will be held virtually online at https://www.cstproxy.com/beneficient/2025.

During the period of the adjournment, the Company will continue to solicit proxies from its stockholders with respect to the proposals set forth in the Company’s proxy statement. Proxies previously submitted in respect to the Annual Meeting will be voted at the reconvened meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action unless they wish to change their vote.

The Company encourages all stockholders who have not yet voted to do so before April 29, 2025, at 11:59 p.m. Central time. The stockholders may vote by internet at https://www.cstproxyvote.com, or by telephone at 1 (866) 894-0536, or by returning a properly executed proxy card to Corporate Secretary, Beneficient, at 325 N. Saint Paul Street, Suite 4850, Dallas, Texas 75201.

  
About Beneficient

Beneficient (Nasdaq: BENF) – Ben, for short – is on a mission to democratize the global alternative asset investment market by providing traditionally underserved investors − mid-to-high net worth individuals, small-to-midsized institutions and General Partners seeking exit options, anchor commitments and valued-added services for their funds− with solutions that could help them unlock the value in their alternative assets. Ben’s AltQuote™ tool provides customers with a range of potential exit options within minutes, while customers can log on to the AltAccess® portal to explore opportunities and receive proposals in a secure online environment.

Its subsidiary, Beneficient Fiduciary Financial, L.L.C., received its charter under the State of Kansas’ Technology-Enabled Fiduciary Financial Institution (TEFFI) Act and is subject to regulatory oversight by the Office of the State Bank Commissioner. 

Additional Information and where to find it

The Company has filed a definitive proxy statement and associated proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the solicitation of proxies for the Annual Meeting of Stockholders of the Company (the “Annual Meeting”). The Company, its directors, its executive officers and certain other individuals set forth in the definitive proxy statement will be deemed participants in the solicitation of proxies from shareholders in respect of the Annual Meeting. Information regarding the names of the Company’s directors and executive officers and certain other individuals and their respective interests in the Company by security holdings or otherwise are set forth in the definitive proxy statement filed with the SEC on March 21, 2025. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO AND ACCOMPANYING PROXY CARD, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and shareholders can obtain a copy of the documents filed by the Company with the SEC, including the definitive proxy statement, free of charge by visiting the SEC’s website, www.sec.gov. The Company’s stockholders can also obtain, without charge, a copy of the definitive proxy statement and other relevant filed documents when available from the Company’s website at www.trustben.com. 

Contact

[email protected]



Everspin Announces Date of First Quarter 2025 Financial Results Conference Call

Everspin Announces Date of First Quarter 2025 Financial Results Conference Call

CHANDLER, Ariz.–(BUSINESS WIRE)–
Everspin Technologies, Inc. (NASDAQ: MRAM), the world’s leading developer and manufacturer of Magnetoresistive Random Access Memory (MRAM) persistent memory solutions, will release its first quarter 2025 financial results after market close on Wednesday, April 30, 2025. Sanjeev Aggarwal, President and Chief Executive Officer, and Bill Cooper, Chief Financial Officer, will host a conference call on Wednesday, April 30at 5:00 p.m. Eastern Time to discuss the Company’s financial results.

What:

Everspin Technologies, Inc. First Quarter 2025 Financial Results Conference Call

When:

Wednesday, April 30, 2025

Time:

5 p.m. ET

Webcast:

https://investor.everspin.com/ (live and replay)

About Everspin Technologies

Everspin Technologies, Inc. is the world’s leading provider of Magnetoresistive RAM (MRAM). Everspin MRAM delivers the industry’s most robust, highest performance non-volatile memory for Industrial IoT, Data Center, and other mission-critical applications where data persistence is paramount. Headquartered in Chandler, Arizona, Everspin provides commercially available MRAM solutions to a large and diverse customer base. For more information, visit www.everspin.com. NASDAQ: MRAM.

Investor Relations

The Blueshirt Group

Monica Gould

212-871-3927

[email protected]

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Automotive Manufacturing Semiconductor Security IOT (Internet of Things) Manufacturing Satellite Other Technology Telecommunications Software Networks Internet Hardware Electronic Design Automation Data Management Consumer Electronics Technology Mobile/Wireless Engineering

MEDIA:

DXC Technology to Report Fourth Quarter and Full Fiscal Year 2025 Results on Wednesday, May 14, 2025

DXC Technology to Report Fourth Quarter and Full Fiscal Year 2025 Results on Wednesday, May 14, 2025

ASHBURN, Va.–(BUSINESS WIRE)–DXC Technology (NYSE: DXC) today announced that it will release its fiscal fourth quarter and full year 2025 financial results on Wednesday, May 14, 2025, at approximately 4:15 p.m. Eastern Time (ET).

Following the release, DXC Technology’s senior management will host a conference call and webcast at 5:00 p.m. ET. The dial-in number for domestic callers is 888-330-2455. Callers who reside outside of the United States should dial +1-240-789-2717. The passcode for all participants is 4164760#. A live webcast will be available on DXC Technology’s Investor Relations website.

A replay of the conference call will be available until 11:59 PM ET on May 21, 2025, at 800-770-2030 for domestic callers and at +1-647-362-9199 for international callers. The replay passcode is 4164760#. A transcript of the conference call will be posted on DXC Technology’s Investor Relations website.

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private, and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.

Forward-Looking Statements

All statements in this press release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. For a written description of these factors, see the section titled “Risk Factors” in DXC’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, and any updating information in subsequent SEC filings. No assurance can be given that any goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events, except as required by law.

Category: Investor Relations

Roger Sachs, CFA

Investor Relations

+1 (201) 259-0801

[email protected]

Suzanne Cross

Corporate Media Relations

+1 (518) 506-8848

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Professional Services Data Management Security Other Professional Services Technology Other Technology Consulting

MEDIA:

Logo
Logo

Walker & Dunlop Announces First Quarter 2025 Earnings Conference Call Details

Walker & Dunlop Announces First Quarter 2025 Earnings Conference Call Details

BETHESDA, Md.–(BUSINESS WIRE)–Walker & Dunlop, Inc. announced today that it will release its first quarter 2025 results before the market opens on May 1, 2025.

The Company will host a conference call to discuss the quarterly results on May 1, 2025, at 8:30 a.m. Eastern time. Listeners can access the call by dialing (888) 394-8218 from within the United States or (773) 305-6853 from outside the United States and are asked to reference the Confirmation Code: 3709282. A simultaneous webcast of the call will be available via the link below:

https://event.webcasts.com/starthere.jsp?ei=1691689&tp_key=b39351272b

A webcast replay will be available on the Investor Relations section of the Company’s website athttps://investors.walkerdunlop.com/.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD) is one of the largest commercial real estate finance and advisory services firms in the United States and internationally. Our ideas and capital create communities where people live, work, shop, and play. Our innovative people, breadth of our brand, and our technological capabilities make us one of the most insightful and client-focused firms in the commercial real estate industry.

Investors:

Kelsey Duffey

Investor Relations

Phone 301.202.3207

[email protected]

Media:

Nina H. von Waldegg

VP, Public Relations

Phone 301.564.3291

[email protected]

Phone 301.215.5500

7272 Wisconsin Avenue, Suite 1300

Bethesda, Maryland 20814

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS: Banking Accounting Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo

GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices

GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices

  • Vaccine recommended to help protect persons over 10 years old in the United States (US) against disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y)
  • Broad serogroup coverage in one vaccine reduces injections to help improve vaccination rates and help protect more US adolescents and young adults
  • Vaccine doses will be ready for use in the US from Summer 2025

PHILADELPHIA–(BUSINESS WIRE)–
GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) as part of the adolescent meningococcal vaccination schedule. Recommendations made by the ACIP are reviewed and, if adopted, are published as official CDC recommendations.

ACIP voted to recommend that persons over 10 years old receive a single dose of PENMENVYas an alternative to separate administration of meningococcal serogroups A, C, W, and Y (MenACWY) and meningococcal serogroup B (MenB) vaccinations when both vaccines would be given on the same clinic visit, typically at age 16. This recommendation, if adopted, will allow for vaccination against serogroups A, B, C, W, and Y in fewer doses, could simplify meningococcal vaccination delivery and could improve immunization rates, helping protect more US adolescents against these five disease-causing serogroups for which the US CDC has previously issued recommendations.1

GSK’s MenABCWY vaccine combines the antigenic components of the Company’s two well-established meningococcal vaccines—BEXSERO(Meningococcal Group B Vaccine) and MENVEO(Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). On February 14, 2025, the US Food and Drug Administration (FDA) approved GSK’s MenABCWY vaccine for use in individuals aged 10 through 25 years.2

Tony Wood, Chief Scientific Officer at GSK, said: “We welcome this positive recommendation that can help strengthen disease prevention efforts in the US. Pentavalent vaccines can reduce the number of injections required to help protect against invasive meningococcal disease – especially disease caused by serogroup B. Their use could improve immunization rates among adolescents and young adults in the US, who are at an age with increased risk.”

Although MenB is the leading cause of invasive meningococcal disease (IMD) among this population, less than 13% of 17-year-olds received the recommended two-dose vaccination series; around 32% received at least one dose according to 2023 CDC survey data.3,4 Three of every four MenB doses currently administered in the US are manufactured by GSK,5 positioning the company well to lead in the US market as MenB-containing vaccination schedules must be completed with the same manufacturer’s MenB vaccine.6

About IMD

IMD is an uncommon but serious illness that can lead to death for up to one in ten of those who contract it in as little as 24 hours from onset, despite treatment.7 IMD is easily misdiagnosed, with early symptoms often mistaken for the flu.7,8 Approximately one in five survivors may experience long-term consequences such as brain damage, amputations, hearing loss, and nervous system problems.8 Although anyone can get IMD, adolescents and young adults between the ages of 16 and 23 years are one of the groups at highest risk due to common behaviors that help transmit the bacteria that cause IMD, such as living in close quarters like college dormitories, kissing and sharing drinks, utensils, or smoking devices.9,10

About PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine)

GSK’s MenABCWY vaccine is an injectable suspension for intramuscular use. The vaccine is supplied as one vial of lyophilized MenACWY Component (powder) which is reconstituted at the time of use with the accompanying prefilled syringe of MenB Component (liquid). In the US, PENMENVY is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in individuals aged 10 through 25 years. The FDA-approved dosing is to administer two doses six months apart. The US Prescribing Information is available here.11

Important Safety Information for PENMENVY in the US

The following is based on the US Prescribing Information for PENMENVY. Please consult the full Prescribing Information for additional safety information.

  • Do not administer PENMENVY to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of PENMENVY, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
  • Syncope (fainting) has occurred in association with administration of PENMENVY
  • PENMENVY may not protect all vaccine recipients and may not provide protection against all meningococcal serogroup B strains
  • Immunocompromised persons, including those receiving immunosuppressive therapy, may have reduced immune responses to PENMENVY
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis, including disease caused by serogroups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENMENVY
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of a U.S.-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENMENVY to persons with a history of GBS should take into account the expected benefits and potential risks
  • The most commonly reported solicited adverse reactions in individuals aged 10 through 25 years after Dose 1 and Dose 2: pain at the injection site, fatigue, headache, myalgia, nausea, erythema, and swelling. The most commonly reported solicited adverse reactions in MenACWY conjugate vaccine-experienced individuals aged 15 through 25 years after Dose 1 and Dose 2: pain at the injection site, headache, fatigue, myalgia, and nausea

About BEXSERO (Meningococcal Group B Vaccine)

GSK’s MenB vaccinehas received regulatory approval in over 55 countries, including the US, and is used in 18 national immunization programs worldwide for the prevention of IMD caused by Neisseria meningitidis serogroup B. More than 110 million doses have been distributed worldwide since 2015.12 Clinical data supported its effectiveness in helping to protect adolescents and young adults against diverse disease-causing strains of MenB, with a well-characterized safety profile. In the US, BEXSERO is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals aged 10 through 25 years. The US Prescribing Information is available here.13

Important Safety Information for BEXSERO in the US

The following is based on the US Prescribing Information for BEXSERO. Please consult the full Prescribing Information for additional safety information.

  • Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO
  • The tip cap of the prefilled syringe may or may not be made with natural rubber latex. Natural rubber latex may cause allergic reactions
  • Syncope (fainting) can occur in association with administration of BEXSERO
  • BEXSERO may not protect all vaccine recipients and may not provide protection against all meningococcal serogroup B strains
  • Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by N. meningitidis serogroup B even after being vaccinated with BEXSERO
  • The most commonly reported solicited adverse reactions: pain at the injection site, fatigue, headache, nausea, erythema, myalgia, and swelling

About MENVEO(Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine)

GSK’s MenACWY vaccinehas received regulatory approval in over 60 countries, including the US, with more than 80 million doses distributed worldwide since 2010.14 It offers evidence of immunogenicity with a well-characterized safety profile. In the US, MENVEO is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections. The US Prescribing Information is available here.15

Important Safety Information for MENVEO in the US

The following is based on the US Prescribing Information for MENVEO. Please consult the full Prescribing Information for additional safety information.

  • Do not administer MENVEO to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of MENVEO, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
  • Syncope (fainting) has occurred in association with administration of MENVEO
  • Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to MENVEO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W, even after being vaccinated with MENVEO
  • Guillain-Barré syndrome has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely
  • Common solicited adverse reactions: at 2 months of age – tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea; at 7 months through 23 months of age – tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea; at 2 through 10 years of age – injection site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Among adolescents and adults aged 11 through 55 years were pain at the injection site, headache, myalgia, malaise, and nausea – similar rates were observed following a booster dose
  • In two clinical studies, there were no notable differences in frequency and severity of solicited adverse reactions in individuals who received MENVEO 1-vial presentation compared to individuals who received the 2-vial presentation
  • Vaccination with MENVEO may not result in protection in all vaccine recipients

About GSK

GSK is a global biopharma Company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

References:

  1. Centers for Disease Control and Prevention. About Meningococcal Vaccines. Available at: https://www.cdc.gov/vaccines/vpd/mening/hcp/about-vaccine.html. Accessed April 2025.
  2. GSK. Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY. Available at: https://www.gsk.com/en-gb/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/. Accessed April 2025.
  3. Cheng WY, et al. Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations. Hum Vaccin Immunother. 2020;16(1):176-188.
  4. Centers for Disease Control and Prevention. National Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2023. Available at: https://www.cdc.gov/mmwr/volumes/73/wr/mm7333a1.htm#:~:text=Among%20adolescents%20aged%2013%E2%80%9317%20years%20included%20in%20the%202023,view%2Fcdc%2F159388. Accessed April 2025.
  5. GSK Data on File Calculation of GSK share in US MenB market January – December 2024. REF-269547. Based on information licensed from IQVIA: IQVIA, DDD, Meningococcal B market all channels, period January – December 2024, reflecting estimates of real-world activity. All rights reserved.
  6. Centers for Disease Control and Prevention. Meningococcal Vaccine Recommendations. Available at: https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html. Accessed April 2025.
  7. Thompson MJ, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  8. Marshall GS, et al. Understanding the Sequelae of Invasive Meningococcal Disease in the United States. Infect Dis Ther. 2024;13(11):2213-2220.
  9. European Centers for Disease Control and Prevention. Outbreak of invasive meningococcal disease in the EU associated with a mass gathering event, the 23rd World Scout Jamboree, in Japan. 21 August 2015. Available at: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Meningococcal-disease-scouts-EU-August-2015.pdf. Accessed April 2025.
  10. Centers for Disease Control and Prevention. Risk Factors for Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/risk-factors/index.html. Accessed April 2025.
  11. GSK. US Prescribing Information for Penmenvy. Available at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Penmenvy/pdf/PENMENVY.PDF. Accessed April 2025.
  12. GSK Data on File. Number of Bexsero doses shipped from 2015 to November 2023 REF-219766
  13. GSK. US Prescribing Information for Bexsero. Available at: gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Bexsero/pdf/BEXSERO.PDF. Accessed April 2025.
  14. GSK Data on File. Menveo Doses Shipped from 2010 to end of 2022 REF-195452.
  15. GSK. Prescribing Information for Menveo. Available at: gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Menveo/pdf/MENVEO.PDF. Accessed April 2025.

GSK enquiries

Media:

Tim Foley +44 (0) 20 8047 5502 (London)

Simon Moore +44 (0) 20 8047 5502 (London)

Kathleen Quinn +1 202 603 5003 (Washington DC)

Alison Hunt +1 540 742 3391 (Washington DC)

Investor Relations:

Annabel Brownrigg-Gleeson +44 (0) 7901 101944 (London)

James Dodwell +44 (0) 20 8047 2406 (London)

Mick Readey +44 (0) 7990 339653 (London)

Camilla Campbell +44 (0) 7803 050238 (London)

Steph Mountifield +44 (0) 7796 707505 (London)

Jeff McLaughlin +1 215 751 7002 (Philadelphia)

Frannie DeFranco +1 215 751 4855 (Philadelphia)

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Research Nursing Infectious Diseases FDA Clinical Trials Biotechnology Health Pharmaceutical Science

MEDIA:

Logo
Logo

CIVISTA BANCSHARES, INC. DECLARES SECOND QUARTER COMMON DIVIDEND

PR Newswire


SANDUSKY, Ohio
, April 16, 2025 /PRNewswire/ — Civista Bancshares, Inc. (NASDAQ: CIVB) (“Civista”) announced today that the Board of Directors has approved a quarterly dividend of 17 cents per common share, equivalent from the prior quarter, to shareholders of record date April 29, 2025, payable May 13, 2025. 

This dividend represents a payout of approximately $2.7 million.  Based on the Civista’s closing stock price of common shares of $19.54 on March 31, 2025, the quarterly dividend produces an annualized yield of 3.38%.


About Civista Bancshares, Inc.:
Civista Bancshares, Inc., is a $4.1 billion financial holding company headquartered in Sandusky, Ohio.  Its primary subsidiary, Civista Bank, was founded in 1884 and provides full-service banking, commercial lending, mortgage, and wealth management services.  Today, Civista Bank operates 42 locations across Ohio, Southeastern Indiana and Northern Kentucky.  Civista Leasing & Finance, a division of Civista Bank, offers commercial equipment leasing services for businesses nationwide.  Civista Bancshares’ common shares are traded on the NASDAQ Capital Market under the symbol “CIVB”.  Learn more at www.civb.com

This press release may contain forward-looking statements regarding the financial performance, business prospects, growth and operating strategies of Civista.  For these statements, Civista claims the protections of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  Statements in this press release should be considered in conjunction with the other information available about Civista, including the information in the filings we make with the Securities and Exchange Commission.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/civista-bancshares-inc-declares-second-quarter-common-dividend-302430646.html

SOURCE Civista Bancshares, Inc.